Bernstein initiated coverage on Amgen with a new price target
$AMGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Bernstein initiated coverage of Amgen with a rating of Outperform and set a new price target of $380.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2024 | $256.00 | Underperform | BofA Securities |
| 11/15/2024 | Peer Perform | Wolfe Research | |
| 11/14/2024 | $335.00 | Neutral | Citigroup |
| 10/17/2024 | $380.00 | Outperform | Bernstein |
| 10/14/2024 | $320.00 → $333.00 | Buy → Hold | Truist |
| 9/27/2024 | $405.00 | Overweight | Cantor Fitzgerald |
| 8/7/2024 | $320.00 → $335.00 | Overweight → Equal Weight | Wells Fargo |
| 5/3/2024 | $230.00 → $300.00 | Underweight → Equal Weight | Barclays |
Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:
Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:
Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:
10-Q - AMGEN INC (0000318154) (Filer)
8-K - AMGEN INC (0000318154) (Filer)
10-Q - AMGEN INC (0000318154) (Filer)
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Approval is based on the pivotal Phase 3 CodeBreaK 300 study, which demonstrated that LUMAKRAS plus Vectibix is the first and only targeted t
THOUSAND OAKS, Calif., Jan. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast avail
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate etakafusp alfa (formerly known as AB248), Asher Bio's investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA® (tarlatamab), Amgen's DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy, in patients with extensive-stage small cell lung cancer (ES-SCLC). "This clinical trial collaboration and supply agreement with Amgen allows us to further expand on the Phase 1 results for etakafusp alfa in a new combination
SC 13G/A - AMGEN INC (0000318154) (Subject)
SC 13G/A - AMGEN INC (0000318154) (Subject)
SC 13D - AMGEN INC (0000318154) (Filed by)
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
BofA Securities resumed coverage of Amgen with a rating of Underperform and set a new price target of $256.00
Wolfe Research initiated coverage of Amgen with a rating of Peer Perform
Citigroup initiated coverage of Amgen with a rating of Neutral and set a new price target of $335.00
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Approval is based on the pivotal Phase 3 CodeBreaK 300 study, which demonstrated that LUMAKRAS plus Vectibix is the first and only targeted t
THOUSAND OAKS, Calif., Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025, to all stockholders of record as of the close of business on February 14, 2025. About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancin
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver
THOUSAND OAKS, Calif., Aug. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately. Dr. Drake will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Governance and Nominating Committee. Following the appointment of Dr. Drake, the Board will be composed of 13 directors, 12 of whom are independent. Dr. Drake is president of the University of California, a system of 10 campuses, five medical centers and three nationally affiliated labs that serves more than 280,000 students and employs 230,000 faculty and staff. "Michael is an accomplished physician an
Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the appointment of Bassem Elmankabadi, M.D., as senior vice president of clinical development. In this role, Dr. Elmankabadi will oversee strategy and execution of Blade's clinical development programs. "Dr. Elmankabadi has an extensive track record driving drug development from proof-of-concept through launch across multiple therapeutic areas," said Wendye Robbins, M.D., president and CEO of Blade. "I am thrilled to welcome Dr. Elmankabadi to the Blade team as we seek to advance our clinical-stage pipeline t
4 - AMGEN INC (0000318154) (Reporting)